Iskanje po repozitoriju

A+ | A- | | SLO | ENG

Povzetek: This real-world study assessed the effectiveness of first-line pembrolizumab monotherapy in patients with metastatic non-oncogene-addicted NSCLC and PD-L1 TPS ≥50%, comparing those aged ≥70 years to younger patients. Results showed no significant differences in outcomes—objective response rate, time on treatment (ToT), and overall survival (OS)—between the two age groups. In older patients, a history of smoking and good performance status (ECOG PS 0–1) were associated with better outcomes. Poor ECOG PS (≥2) was linked to shorter ToT and OS, regardless of age. Older patients were less likely to receive second-line therapy due to comorbidities and functional decline. These findings highlight the importance of performance status over chronological age in predicting benefit from immunotherapy and support pembrolizumab monotherapy as an effective firstline option for older patients with good functional status.
Ključne besede: NSCLC, PD-L1, real-world data
Objavljeno v DiRROS: 25.02.2026; Ogledov: 291; Prenosov: 140
Celotno besedilo (1,85 MB)
Gradivo ima več datotek! Več...

Povzetek: BRAF and cMET exon 14 skipping are rare mutations of NSCLC. The treatment sequence in these cases for the first and second line is not clear. An international registry was created for patients with advanced NSCLC harboring BRAF or cMET exon 14 skipping mutations, diagnosed from January 2017 to June 2022. Clinicopathological and molecular data and treatment patterns were recorded. Data on 58 patients, from eight centers across five countries, were included in the final analysis. We found that 40 patients had the cMET exon 14 skipping mutation and 18 had the BRAF V600E mutation. In total, 53 and 28 patients received first- and second-line treatments, respectively, among which 52.8% received targeted therapy (TT) in the first line and 53.5% in the second line. The overall response rate (ORR) and disease control rate (DCR) for first-line treatment with TT vs. other treatment such as immune checkpoint inhibitors ± chemotherapy (IO ± CT) were 55.6% vs. 21.7% (p = 0.0084) and 66.7% vs. 39.1% (p = 0.04), respectively. The type of treatment in first-line TT vs. other affected time to treatment discontinuation (TTD) was 11.6 m vs. 4.6 m (p= 0.006). The overall survival for the whole group was 15.4 m and was not statistically affected by the type of treatment (19.2 m vs. 13.5 m; p = 0.83).
Ključne besede: non-small-cell lung cancer, BRAF V600 mutation, cMET exon 14 skipping mutation, real-world data, targeted therapy, first-line therapy
Objavljeno v DiRROS: 25.02.2026; Ogledov: 273; Prenosov: 146
Celotno besedilo (305,90 KB)
Gradivo ima več datotek! Več...

Povzetek: Background: The recommended booster third dose of vaccination against COVID-19 in cancer patients seems reasonable to protect them against a severe disease course. A prospective study was designed to assess the immunogenicity, efficacy, and safety of COVID-19 vaccination in this cohort. Methods: Patients with solid malignancies on active treatment were followed up after the primary course and booster third dose of vaccination to assess their anti-SARS-CoV-2 S1 IgG levels, efficacy in the case of SARS-CoV-2 infection, and safety. Results: Out of 125 patients receiving the primary course of vaccination, 66 patients received a booster third dose of mRNA vaccine, with a 20-fold increase in median anti-SARS-CoV-2 S1 IgG levels compared to Ab levels six months post-primary course of vaccination (p < 0.0001). After the booster third dose, anti-SARS-CoV-2 S1 IgG levels were comparable to healthy controls (p = 0.113). There was a decline in Ab levels 3 (p = 0.0003) and 6 months (p < 0.0001) post-third booster dose. No patients had either a severe disease course or a lethal outcome in the case of SARS-CoV-2 infection after the third booster dose. Conclusion: The third booster vaccination dose against COVID-19 in solid cancer patients triggers substantial immunogenicity and is safe and effective for preventing a severe COVID-19 disease course.
Ključne besede: solid cancer, COVID-19 vaccination, booster third dose
Objavljeno v DiRROS: 25.02.2026; Ogledov: 253; Prenosov: 142
Celotno besedilo (1,55 MB)
Gradivo ima več datotek! Več...

Ključne besede: nedrobnocelični rak pljuč, neoadjuvantno zdravljenje, molekularni profil
Objavljeno v DiRROS: 19.11.2025; Ogledov: 339; Prenosov: 187
Celotno besedilo (1,24 MB)
Gradivo ima več datotek! Več...

Povzetek: Cytokine release syndrome (CRS) is a well-described immune-related adverse event following chimeric antigen receptor T-cell therapy (CAR-T) but has rarely been reported following therapy with immune checkpoint inhibitors (ICI). We present a clinical case of severe CRS after ICI therapy for advanced non-small-cell lung cancer (NSCLC). After the third cycle of ipilimumab and nivolumab the patient presented with fever, hypotension and somnolence, leading to acute respiratory failure, acute kidney and hepatic failure, capillary leak syndrome, requiring ICU (intensive care unit) care. She recovered after receiving tocilizumab and steroid therapy. Subsequently, we found 17 clinical cases of advanced NSCLC patients in peer review, experiencing CRS as an adverse event of treatment with ICI. We review those cases in detail and compare the similarities and outcomes. Conclusion: CRS is a serious, life-threatening complication that is rare after ICI therapy for solid cancers but becoming increasingly frequent since ICI therapies are broadening indications. When presented with clinical symptoms, considering CRS is crucial, as early recognition is key to timely intervention and favorable outcome for the patient.
Ključne besede: on-small-cell lung cancer, immune checkpoint inhibitors, cytokine release syndrome, immune- related adverse events, case report
Objavljeno v DiRROS: 22.08.2025; Ogledov: 597; Prenosov: 326
Celotno besedilo (1,32 MB)
Gradivo ima več datotek! Več...